Delayed in vivo disease progression is associated with high proportions of CD45+ myeloma cells in the 5T2MM murine model.
Both CD45(+) and CD45(-) multiple myeloma (MM) cells are observed in the bone marrow (BM) of MM patients; however, their impact on the outcome of the disease is unknown. Most (92%) of the mice injected with murine 5T2MM cells develop myeloma in 10-12 weeks and show hind leg paralysis at the end phase of the disease. In the end stage 5T2MM cells are predominantly CD45(-), in analogy to the common human situation. Herein we report that 8% of the mice have a delayed tumor progression (14-24 weeks) with a complete different feature in the end stage of the disease. These animals had typically a bowed back and never got paralyzed. The MM cells in the BM of these mice were predominantly CD45(+). These data indicate that CD45 subsets are associated with the final outcome of myeloma disease.
Asosingh
Kewal
K
Department of Hematology and Immunology, Vrije Universiteit Brussel-VUB, B-1090 Brussels, Belgium. Kewal.Asosingh@vub.ac.be
Willems
Angelo
A
Van Riet
Ivan
I
Van Camp
Benjamin
B
Vanderkerken
Karin
K
D000375:Aging; D000818:Animals; D000951:Antigens, Neoplasm / Q000032:analysis*; D018450:Disease Progression; D016130:Immunophenotyping; D007738:Kyphosis / Q000209:etiology; D017493:Leukocyte Common Antigens / Q000032:analysis*; D051379:Mice; D008810:Mice, Inbred C57BL; D009101:Multiple Myeloma / Q000150:complications / Q000378:metabolism / Q000473:pathology*; D009368:Neoplasm Transplantation; D014411:Neoplastic Stem Cells / Q000737:chemistry* / Q000473:pathology; D010257:Paraneoplastic Syndromes / Q000209:etiology; D010264:Paraplegia / Q000209:etiology
D000951:Antigens, Neoplasm; D017493:Leukocyte Common Antigens